Pharmacology of tyrosine kinase inhibitors in chronic myeloid leukemia; a clinician’s perspective
Pharmacology of tyrosine kinase inhibitors in chronic myeloid leukemia; a clinician’s perspective
About this item
Full title
Author / Creator
Publisher
Cham: Springer International Publishing
Journal title
Language
English
Formats
Publication information
Publisher
Cham: Springer International Publishing
Subjects
More information
Scope and Contents
Contents
Objective
In this review, we have summarized the pharmacokinetics, pharmacodynamics and adverse effects of imatinib, dasatinib, nilotinib, bosutinib, ponatinib and radotinib with focus on pharmacogenomic studies with clinical end points. We have discussed the key phase 3 trials of tyrosine kinase inhibitors (TKI) comparing with each other, treat...
Alternative Titles
Full title
Pharmacology of tyrosine kinase inhibitors in chronic myeloid leukemia; a clinician’s perspective
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7214547
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7214547
Other Identifiers
ISSN
2008-2231,1560-8115
E-ISSN
2008-2231
DOI
10.1007/s40199-019-00321-z
